ArticleInternational breastfeeding journal2025
Risk factors for treatment failure in lactational mastitis: a retrospective cohort study in China.
Article in International breastfeeding journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLactation mastitis is a common postpartum disease. Flucloxacillin is frequently used for treatment, but its efficacy is limited in some cases, potentially causing adverse outcomes such as premature cessation of breastfeeding. This study aimed to identify risk factors for poor treatment outcomes in lactational mastitis managed with flucloxacillin and provide evidence for precise clinical management.
methodsA retrospective cohort study was conducted from January to December 2022 at the Chongqing Health Center for Women and Children in China. It included 133 hospitalized patients with acute lactational mastitis treated with flucloxacillin, divided into effective treatment (n = 93) and treatment failure (n = 40) groups. Effective treatment was defined as clinical improvement characterized by a reduction in breast pain and swelling, along with normalization of body temperature within 48 hours of initiating flucloxacillin therapy. Treatment failure was defined as the absence of clinical improvement or worsening of symptoms, necessitating a change in the antimicrobial regimen. Data on patient demographic and clinical characteristics, laboratory findings, and treatment outcomes were collected and analyzed.
resultsAmong 133 patients, 93 (69.9%) were effectively treated with flucloxacillin, while 40 (30.1%) experienced treatment failure. Binary logistic regression identified onset time ≥3 days (Adjusted OR 2.76, 95% CI 1.22, 6.28) and inflammation located in the nipple/areola area (Adjusted OR 3.28, 95% CI 1.27, 8.49) as independent risk factors for treatment failure. The treatment failure group had longer median fever duration (3 days vs. 1 day, p < 0.001), longer median hospital stay (7 days vs. 4 days, p < 0.001), higher median hospitalization costs (3868 yuan [US$553] vs. 2000 yuan [US$286], p < 0.001), and higher lactation suppression rates (20% vs. 2.2%, p = 0.001). Staphylococcus aureus was the predominant isolate, with a higher isolation rate in the treatment effective group (88% vs. 50%, OR 7.0, 95% CI 1.78, 27.42).
conclusionsThe present study identified that treatment failure of flucloxacillin for acute lactational mastitis was significantly associated with disease onset ≥3 days, inflammation in the nipple/areola area, and non-Staphylococcus aureus infections. Early identification and intervention are essential for better outcomes. Developing guidelines that emphasize early intervention may contribute to reducing fever duration, patient discomfort, breastfeeding cessation rates, and healthcare burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.